When it comes to navigating long-acting reversible contraception (LARC) options, intrauterine devices, better known as IUDs, ...

SAN FRANCISCO and DUBLIN, Oct. 28, 2019 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, and Allergan plc (NYSE: AGN), a ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Levonorgestrel ...

IUD insertion tube. A levonorgestrel 52-mg intrauterine system was found to be safe and effective for pregnancy prevention. A levonorgestrel 52-mg intrauterine system (IUS) was found to be safe and ...

The Liletta levonorgestrel-releasing intrauterine device decreased bleeding in those with heavy menstrual bleeding. Reduced bleeding also had a substantial impact on quality of life. BALTIMORE — ...

ABSTRACT Unintended pregnancy is reportedly higher in active duty women; therefore, we sought to estimate the potential impact of the levonorgestrel-containing intrauterine system (LNG-IUS) could have ...

Hazard ratios were 1.3, 1.4, and 1.8 for 0 to 5, 5 to 10, and more than 10 to 15 years of use, respectively, compared with the corresponding durations of nonuse, resulting in an excess of 14, 29, and ...

U.S. FDA APPROVES BAYER'S SKYLA™(LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM) 13.5 mg FOR PREVENTION OF PREGNANCY FOR UP TO THREE YEARS Wayne, NJ, January 9, 2013 – Bayer HealthCare Pharmaceuticals ...

The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Mirena (levonorgestrel-releasing intrauterine system; Bayer), to extend the indication to up to 6 ...

Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer. Breast ...

WHIPPANY, N.J., Oct. 21, 2019 /PRNewswire/ -- Bayer, a leader in women's healthcare, announced today the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a leader in women's healthcare, announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) that ...